Latest Delcath Systems (DCTH) Headlines
Delcath Reports 2013 Fourth Quarter And Full Year Results
PR Newswire - Wed Mar 12, 3:01PM CDT
Delcath Systems, Inc. (NASDAQ: DCTH) today reported financial results and operational developments for the fiscal fourth quarter and full year ended December 31, 2013. Developments for the quarter and recent weeks subsequent to quarter end are as follows:
Northwest Bio's German Smokescreen Obscures DCVax Problems
at The Street - Tue Mar 11, 1:44PM CDT
Northwest Bio received good news from Germany in February but didn't tell investors until Monday.
Form 4: Update Filing for National CineMedia Inc (NCMI)
Vickers Stock Research - Thu Feb 27, 9:20AM CST
Meeting to be Held May 2, 2013
DELCATH TO REPORT 2013 FOURTH QUARTER AND FULL YEAR RESULTS ON MARCH 12, 2014
Thomson Reuters ONE - Tue Feb 25, 3:05PM CST
NEW YORK, NY - February 25, 2014 - Delcath Systems, Inc. (NASDAQ: DCTH) today announced that it will host a conference call and webcast on Wednesday, March 12, 2014 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year of 2013 ended December 31, 2013, and provide an update on recent corporate progress.
4 Stocks Under $10 Making Big Moves
at The Street - Fri Feb 14, 5:30AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
8-K: NuStar Energy L.P.
Edgar Online - Tue Feb 04, 12:35AM CST
NS 8-K Press Release 2.03.14
DELCATH ANNOUNCES REIMBURSEMENT STATUS FOR CHEMOSAT IN GERMANY
Thomson Reuters ONE - Fri Jan 31, 9:31AM CST
Interim Reimbursement Value 4 Status Confirmed for 2014
Honeywell And Stor Generation Connect With Building Owners To Stabilize Electrical Grid, Help Avoid Outages
PR Newswire - Thu Jan 30, 6:00AM CST
Honeywell (NYSE: HON) and power management company Stor Generation Ltd. have launched a new, first-of-its-kind smart grid program in the U.K. The companies will use Honeywell technology to temporarily trim energy use in commercial and industrial facilities, combining the excess power to help stabilize the electrical grid, and address country-wide carbon reduction and renewable energy commitments.
Glu Mobile Adds an Arsenal of New Titles to Give â??Deer Hunter' Company: Glu Mobile Inc. (NASDAQ: GLUU), Aeterna Zentaris Inc. (NASDAQ: AEZS), Vical Inc. (NASDAQ:VICL), Delcath Systems Inc. (NASDAQ: DCTH)
ACCESSWIRE - Tue Jan 28, 10:04AM CST
When smartphones meet free-to-play games it creates a business model that game maker Glu Mobile Inc. (NASDAQ: GLUU) is exploiting to the hilt.
Most active Nasdaq-traded stocks
AP - Thu Jan 16, 5:02PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Quick Market Round-up before the Bell: Delcath Systems, Valeant Pharma Intl., BioMarin Pharma, and Insmed
PR Newswire - Thu Jan 09, 7:00AM CST
On Wednesday, January 08, 2014, the US equity market ended on a mixed note. The S&P 500 ended the day 0.02% lower at 1,837.49; the Dow Jones Industrial Average finished 0.41% lower at 16,462.74; and the NASDAQ Composite closed 0.30% higher at 4,165.61. The S&P 500 Health Care Sector Index edged 0.88% higher to end the day at 649.79; and the same has gained 1.89% in the last one month and 12.44% in the previous three months, outperforming the S&P 500, which has advanced 1.79% and 11.00% during the respective periods. The major movers in the Health Care sector included Delcath Systems Inc. (NASDAQ: DCTH), Valeant Pharmaceuticals International Inc. (NYSE: VRX), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and Insmed Inc. (NASDAQ: INSM). AAAResearchReports.com has released full comprehensive research on DCTH, VRX, BMRN, and INSM. These free technical analyses can be downloaded by signing up at:
DELCATH ANNOUNCES EXTENSION TO REGAIN COMPLIANCE WITH NASDAQ'S MINIMUM BID PRICE RULE
Thomson Reuters ONE - Fri Dec 13, 5:31AM CST
Company Intends to Hold a Special Shareholder Meeting to Authorize Reverse Stock Split
Daily Trends Scanner: BioMarin Pharma Inc., Delcath Systems Inc., Akorn Inc., and Insmed Inc.
PR Newswire - Wed Dec 11, 9:19AM CST
Editor Note: For more information about this release, please scroll to bottom.
Global Neuroendocrine Tumors Report 2013
M2 - Mon Nov 18, 3:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/kps7rj/neuroendocrine) has announced the addition of the "Global Neuroendocrine Tumors Report 2013" report to their offering. 'Neuroendocrine Tumors - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Neuroendocrine Tumors, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neuroendocrine Tumors. This analysis is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Neuroendocrine Tumors. - A review of the Neuroendocrine Tumors products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Neuroendocrine Tumors pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Neuroendocrine Tumors. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Neuroendocrine Tumors pipeline depth and focus of Indication therapeutics. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Neuroendocrine Tumors Overview Therapeutics Development An Overview of Pipeline Products for Neuroendocrine Tumors Companies Involved in Neuroendocrine Tumors Therapeutics Development Drug Profiles - MK-2206 - panobinostat - DG-3173 - everolimus - everolimus - edotreotide Labeled Yttrium 90 - edotreotide Labeled Yttrium 90 - TH-302 - lanreotide acetate - melphalan - IT-139 - vantictumab - 177Lu-DOTA-TATE - pasireotide LAR - Peptides For Cancer Featured News & Press Releases Appendix Companies Mentioned - Delcath Systems - Gradalis - Ipsen - Merck & Co - Nobelpharma - Novartis - OncoMed Pharmaceuticals - Progenics Pharmaceuticals - Tekmira Pharmaceuticals - Threshold Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/kp...oendocrine
Pre-Market Review: Delcath Systems Inc., BioMarin Pharma Inc., Insmed Inc., and Akorn Inc.
PR Newswire - Fri Nov 15, 7:00AM CST
On Thursday, November 14, 2013, all three indexes of the US equity market posted gains. The S&P 500 ended the day at 1,790.62, up 0.48%; the Dow Jones Industrial Average closed at 15,876.22, up 0.35%; and the NASDAQ Composite finished at 3,972.74, up 0.18%. Shares in the healthcare sector mostly ended on a lower note, even as the broader market posted gains. The major movers in the sector included Delcath Systems Inc. (NASDAQ: DCTH), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Insmed Inc. (NASDAQ: INSM), and Akorn Inc. (NASDAQ: AKRX). AAAResearchReports.com initiated preliminary technical research on DCTH, BMRN, INSM, and AKRX. These free reports are accessible by signing today at:
Delcath Reports 2013 Third Quarter Results
PR Newswire - Wed Nov 06, 3:05PM CST
Delcath Systems, Inc. (NASDAQ: DCTH) today reported financial results and operational developments for the fiscal third quarter and nine months ended September 30, 2013. Developments for the quarter and recent weeks subsequent to quarter end are as follows:
Pre-Market Analysis: BioMarin Pharma Inc., Insmed Inc., Delcath Systems Inc., and Akorn Inc.
PR Newswire - Fri Oct 25, 10:34AM CDT
Editor Note: For more information about this release, please scroll to bottom.
DELCATH TO RAISE APPROXIMATELY $7.5 MILLION
Thomson Reuters ONE - Wed Oct 23, 7:47AM CDT
New York, NY -October 23, 2013 - Delcath Systems, Inc. (NASDAQ: DCTH) today announced that it is raising approximately $7.5 million in gross proceeds in an offering of 20,960,000 shares of its common stock and warrants to purchase up to 9,432,000 shares of common stock at a combined price to the public of $0.36 per share and related warrant. The warrants are exercisable beginning on the date six months after the date of issuance at an exercise price of $0.44 per share and will expire, unless exercised, on the fifth anniversary of the date of issuance.
5 Stocks Under $10 Set to Soar
at The Street - Thu Oct 17, 2:14PM CDT
DELCATH TO REPORT THIRD QUARTER 2013 RESULTS ON NOVEMBER 6, 2013
Thomson Reuters ONE - Fri Oct 11, 9:45AM CDT
NEW YORK, NY - October 11, 2013 - Delcath Systems, Inc. (NASDAQ: DCTH) today announced that it will host a conference call and webcast on Wednesday, November 6, 2013 at 4:30 p.m. ET to discuss its financial results for the third quarter of 2013 ended September 30, 2013, and provide an update on recent corporate progress.
Delcath Reports 2013 Fourth Quarter And Full Year Results
PR Newswire - Wed Mar 12, 3:01PM CDT
Delcath Systems, Inc. (NASDAQ: DCTH) today reported financial results and operational developments for the fiscal fourth quarter and full year ended December 31, 2013. Developments for the quarter and recent weeks subsequent to quarter end are as follows:
Northwest Bio's German Smokescreen Obscures DCVax Problems
at The Street - Tue Mar 11, 1:44PM CDT
Northwest Bio received good news from Germany in February but didn't tell investors until Monday.
Form 4: Update Filing for National CineMedia Inc (NCMI)
Vickers Stock Research - Thu Feb 27, 9:20AM CST
Meeting to be Held May 2, 2013
DELCATH TO REPORT 2013 FOURTH QUARTER AND FULL YEAR RESULTS ON MARCH 12, 2014
Thomson Reuters ONE - Tue Feb 25, 3:05PM CST
NEW YORK, NY - February 25, 2014 - Delcath Systems, Inc. (NASDAQ: DCTH) today announced that it will host a conference call and webcast on Wednesday, March 12, 2014 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year of 2013 ended December 31, 2013, and provide an update on recent corporate progress.
4 Stocks Under $10 Making Big Moves
at The Street - Fri Feb 14, 5:30AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
8-K: NuStar Energy L.P.
Edgar Online - Tue Feb 04, 12:35AM CST
NS 8-K Press Release 2.03.14
DELCATH ANNOUNCES REIMBURSEMENT STATUS FOR CHEMOSAT IN GERMANY
Thomson Reuters ONE - Fri Jan 31, 9:31AM CST
Interim Reimbursement Value 4 Status Confirmed for 2014
Honeywell And Stor Generation Connect With Building Owners To Stabilize Electrical Grid, Help Avoid Outages
PR Newswire - Thu Jan 30, 6:00AM CST
Honeywell (NYSE: HON) and power management company Stor Generation Ltd. have launched a new, first-of-its-kind smart grid program in the U.K. The companies will use Honeywell technology to temporarily trim energy use in commercial and industrial facilities, combining the excess power to help stabilize the electrical grid, and address country-wide carbon reduction and renewable energy commitments.
Glu Mobile Adds an Arsenal of New Titles to Give â??Deer Hunter' Company: Glu Mobile Inc. (NASDAQ: GLUU), Aeterna Zentaris Inc. (NASDAQ: AEZS), Vical Inc. (NASDAQ:VICL), Delcath Systems Inc. (NASDAQ: DCTH)
ACCESSWIRE - Tue Jan 28, 10:04AM CST
When smartphones meet free-to-play games it creates a business model that game maker Glu Mobile Inc. (NASDAQ: GLUU) is exploiting to the hilt.
Most active Nasdaq-traded stocks
AP - Thu Jan 16, 5:02PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Quick Market Round-up before the Bell: Delcath Systems, Valeant Pharma Intl., BioMarin Pharma, and Insmed
PR Newswire - Thu Jan 09, 7:00AM CST
On Wednesday, January 08, 2014, the US equity market ended on a mixed note. The S&P 500 ended the day 0.02% lower at 1,837.49; the Dow Jones Industrial Average finished 0.41% lower at 16,462.74; and the NASDAQ Composite closed 0.30% higher at 4,165.61. The S&P 500 Health Care Sector Index edged 0.88% higher to end the day at 649.79; and the same has gained 1.89% in the last one month and 12.44% in the previous three months, outperforming the S&P 500, which has advanced 1.79% and 11.00% during the respective periods. The major movers in the Health Care sector included Delcath Systems Inc. (NASDAQ: DCTH), Valeant Pharmaceuticals International Inc. (NYSE: VRX), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and Insmed Inc. (NASDAQ: INSM). AAAResearchReports.com has released full comprehensive research on DCTH, VRX, BMRN, and INSM. These free technical analyses can be downloaded by signing up at:
DELCATH ANNOUNCES EXTENSION TO REGAIN COMPLIANCE WITH NASDAQ'S MINIMUM BID PRICE RULE
Thomson Reuters ONE - Fri Dec 13, 5:31AM CST
Company Intends to Hold a Special Shareholder Meeting to Authorize Reverse Stock Split
Daily Trends Scanner: BioMarin Pharma Inc., Delcath Systems Inc., Akorn Inc., and Insmed Inc.
PR Newswire - Wed Dec 11, 9:19AM CST
Editor Note: For more information about this release, please scroll to bottom.
Global Neuroendocrine Tumors Report 2013
M2 - Mon Nov 18, 3:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/kps7rj/neuroendocrine) has announced the addition of the "Global Neuroendocrine Tumors Report 2013" report to their offering. 'Neuroendocrine Tumors - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Neuroendocrine Tumors, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neuroendocrine Tumors. This analysis is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Neuroendocrine Tumors. - A review of the Neuroendocrine Tumors products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Neuroendocrine Tumors pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Neuroendocrine Tumors. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Neuroendocrine Tumors pipeline depth and focus of Indication therapeutics. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Neuroendocrine Tumors Overview Therapeutics Development An Overview of Pipeline Products for Neuroendocrine Tumors Companies Involved in Neuroendocrine Tumors Therapeutics Development Drug Profiles - MK-2206 - panobinostat - DG-3173 - everolimus - everolimus - edotreotide Labeled Yttrium 90 - edotreotide Labeled Yttrium 90 - TH-302 - lanreotide acetate - melphalan - IT-139 - vantictumab - 177Lu-DOTA-TATE - pasireotide LAR - Peptides For Cancer Featured News & Press Releases Appendix Companies Mentioned - Delcath Systems - Gradalis - Ipsen - Merck & Co - Nobelpharma - Novartis - OncoMed Pharmaceuticals - Progenics Pharmaceuticals - Tekmira Pharmaceuticals - Threshold Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/kp...oendocrine
Pre-Market Review: Delcath Systems Inc., BioMarin Pharma Inc., Insmed Inc., and Akorn Inc.
PR Newswire - Fri Nov 15, 7:00AM CST
On Thursday, November 14, 2013, all three indexes of the US equity market posted gains. The S&P 500 ended the day at 1,790.62, up 0.48%; the Dow Jones Industrial Average closed at 15,876.22, up 0.35%; and the NASDAQ Composite finished at 3,972.74, up 0.18%. Shares in the healthcare sector mostly ended on a lower note, even as the broader market posted gains. The major movers in the sector included Delcath Systems Inc. (NASDAQ: DCTH), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Insmed Inc. (NASDAQ: INSM), and Akorn Inc. (NASDAQ: AKRX). AAAResearchReports.com initiated preliminary technical research on DCTH, BMRN, INSM, and AKRX. These free reports are accessible by signing today at:
Delcath Reports 2013 Third Quarter Results
PR Newswire - Wed Nov 06, 3:05PM CST
Delcath Systems, Inc. (NASDAQ: DCTH) today reported financial results and operational developments for the fiscal third quarter and nine months ended September 30, 2013. Developments for the quarter and recent weeks subsequent to quarter end are as follows:
Pre-Market Analysis: BioMarin Pharma Inc., Insmed Inc., Delcath Systems Inc., and Akorn Inc.
PR Newswire - Fri Oct 25, 10:34AM CDT
Editor Note: For more information about this release, please scroll to bottom.
DELCATH TO RAISE APPROXIMATELY $7.5 MILLION
Thomson Reuters ONE - Wed Oct 23, 7:47AM CDT
New York, NY -October 23, 2013 - Delcath Systems, Inc. (NASDAQ: DCTH) today announced that it is raising approximately $7.5 million in gross proceeds in an offering of 20,960,000 shares of its common stock and warrants to purchase up to 9,432,000 shares of common stock at a combined price to the public of $0.36 per share and related warrant. The warrants are exercisable beginning on the date six months after the date of issuance at an exercise price of $0.44 per share and will expire, unless exercised, on the fifth anniversary of the date of issuance.
5 Stocks Under $10 Set to Soar
at The Street - Thu Oct 17, 2:14PM CDT
DELCATH TO REPORT THIRD QUARTER 2013 RESULTS ON NOVEMBER 6, 2013
Thomson Reuters ONE - Fri Oct 11, 9:45AM CDT
NEW YORK, NY - October 11, 2013 - Delcath Systems, Inc. (NASDAQ: DCTH) today announced that it will host a conference call and webcast on Wednesday, November 6, 2013 at 4:30 p.m. ET to discuss its financial results for the third quarter of 2013 ended September 30, 2013, and provide an update on recent corporate progress.
